



DEPARTMENT OF THE NAVY
BUREAU OF MEDICINE AND SURGERY
2300 E STREET NW
WASHINGTON DC 20372-5300

IN REPLY REFER TO
6530/2.5
Ser M3F2/0060
4 Jun 03

From: Chief, Bureau of Medicine and Surgery

Subj: REVISED GUIDELINES FOR WEST NILE VIRUS (WNV) SCREENING,
DEFERRAL, TESTING, AND LOOKBACK

Ref: (a) ASBPO BPL 03-07 of 2 Jun 03
(b) FDA Guidance for Industry, Revised Recommendations for
the Assessment of Donor Suitability and Blood and Blood
Product Safety in Cases of Known or Suspected West Nile
Virus Infection, May 2003
(c) BUMED ltr 6530/2.5 Ser M3F2/0085 of 27 Nov 02

Encl: (1) Navy Blood Program Office Policy on Blood Donor
Screening, Deferral, and Lookback for West Nile Virus
(WNV), 4 Jun 03
(2) NBPO Donor Center Personnel Instructions for Direct
Oral Question (DOQ) for West Nile Virus (WNV), 4 Jun 03
(3) Acknowledgement and Implementation Form

1. The Navy Blood Program Office (NBPO) provides procedural guidance and operational policies for Navy and Marine Corps facilities responsible for collection, storage, and/or transfusion of blood products. The NBPO is revising the guidelines for blood donor screening, deferral, testing, and lookback for WNV that is consistent with both Armed Services Blood Program Office (ASBPO) policy and guidance from the Food and Drug Administration (FDA) in references (a) and (b). Reference (c) provided interim guidance to prevent the transfusion transmission of WNV and is rescinded upon implementation of this guidance. Nucleic Acid Testing (NAT) for WNV will be implemented under an investigational new drug (IND) protocol and will be required on or about July 01, 2003.

2. Navy Blood Donor Centers (BDC) are to implement the Navy Blood Program Office Policy on Blood Donor Screening, Deferral, Testing, and Lookback for WNV (enclosure (1)) which meets the FDA guideline. Allogeneic and autologous donors are to receive the WNV Information Sheet (enclosure 1, Attachment A) with other Donor Information Literature. During the interview, the screener will ask, verbatim, the WNV-direct oral question in enclosure (2) and will document the donor's response according to established procedures in Section V of the Blood Donation Record (DD Form 572).

Subj: REVISED GUIDELINES FOR WEST NILE VIRUS (WNV) SCREENING,
DEFERRAL, TESTING, AND LOOKBACK

3. All Navy facilities must follow the donor and patient lookback policy for WNV when a donor tests positive for WNV or WNV related post donation information is received, or when a recipient with a recent diagnosis of WNV who received a blood transfusion or organ donation is identified (enclosure (1)). Report cases of WNV infection to the Navy Environmental Health Center, Norfolk, Virginia (757) 953-0700.

4. A Biological Product Deviation report will be required if post-donation information related to WNV is received in cases where product retrieval and quarantine and/or notification of recipients of prior or subsequent collections from the donor occurs. If a suspect donation results in fatality in a transfusion recipient, a report of the fatality must be submitted to the FDA.

5. Each BDC must incorporate this change into appropriate standard operating procedures (SOP), validate, and train staff to insure the policy is adequately implemented as soon as possible but not later than **13 Jun 03**. The incorporation of this policy on WNV into your facility specific SOPs will not require additional changes to the blood donor medical conditions and medication lists. All navy facilities are to return enclosure (3) to BUMED-M3F2 by **13 Jun 03** to indicate receipt of the policy and dissemination to management staff and appropriate healthcare providers.

6. Points of contact for this matter are Ms. Jan Sigmon, QA Manager, or myself at DSN 762-3434 or (202) 762-3434.



M. C. LIBBY
By direction

Distribution:

NATNAVMEDCEN Bethesda MD
NAVHOSP Camp Lejeune NC
NAVHOSP Great Lakes IL
NAVMEDCEN Portsmouth VA

NAVMEDCEN San Diego CA
USNAVHOSP Okinawa JA
USNAVHOSP Guam

Copy to: Cont'd on next page

Subj: REVISED GUIDELINES FOR WEST NILE VIRUS (WNV) SCREENING,
DEFERRAL, TESTING, AND LOOKBACK

Copy to: Cont'd

NAVHOSP Bremerton WA	USNAVHOSP Roosevelt Roads PR
NAVHOSP Camp Pendleton CA	USNAVHOSP Naples IT
NAVHOSP Charleston SC	USNAVHOSP Rota SP
NAVHOSP Cherry Point NC	USNAVHOSP Sigonella IT
NAVHOSP Jacksonville FL	USNAVHOSP Yokosuka JA
NAVHOSP Lemoore CA	USNAVHOSP Guantanamo Bay CU
NAVHOSP Oak Harbor WA	USNAVHOSP Keflavik IC
NAVHOSP Pensacola FL	CNO (N931) Washington DC
ASBPO Washington DC	COMPACFLT Pearl Harbor HI
CDR USAMEDCOM FT Sam Houston TX	COMLANTFLT Norfolk VA
HQ USAF Bolling AFB DC	COMUSNAVEUR Naples IT
USJFCOM Norfolk VA	USPACOM JBPO Okinawa JA
USNS MERCY	USNS COMFORT
NEHC Norfolk VA	

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV)

Purpose Establish revised policy regarding blood donor screening, deferral and lookback for West Nile Virus. This policy applies to collections of Whole Blood, blood components (including recovered plasma), Source Plasma and Source Leukocytes collected from allogeneic and autologous donors intended either for use in transfusion or for further manufacture into injectable and non-injectable products. Update applicable Standardized Operating Procedures (SOP) in accordance with (IAW) this policy.

Background WNV is primarily transmitted in birds through mosquito bites. Humans are incidental hosts. WNV is associated with human encephalitis and meningitis. In 2002, a major outbreak of WNV was detected in many parts of the United States. The number of human cases of WNV illness in 2002 totaled 4161 and 277 deaths were reported as of March 12, 2003. The 2002 WNV epidemic involved the first documented cases of WNV transmission through blood transfusion, organ transplantation, intrauterine infection, and possibly breastfeeding. Since 80% of persons infected with WNV do not develop any illness and remain asymptomatic, even while transiently viremic, careful predonation screening and WNV testing of blood and plasma donors for WNV is necessary to reduce the risk of WNV infection through blood transfusion.

Definitions The following definitions apply to WNV in this policy:

Term	Definition
Symptoms of WNV Infection	<ul style="list-style-type: none"> • Measured fever [temperature greater than 100.4 °F (38°C)] AND • One or more flu-like symptom suggestive of WNV infection (e.g. headache, eye pain, body aches, generalized weakness, new generalized skin rash, swollen lymph nodes) • Additional information available on CDC website: http://www.cdc.gov/ncidod/dvbid/westnile/clinical_guidance.htm OR www.cdc.gov/ncidod/dvbid/westnile/city_states.htm

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Definitions (continued)

Term	Definition
Measured Fever	<ul style="list-style-type: none"> • Temperature greater than 100.4 °F (38°C)
Medical Diagnosis of WNV Infection	<ul style="list-style-type: none"> • Current or recent illness compatible with WNV AND • Positive test for WNV IgM antibodies
Suspect Donation(s)	<ul style="list-style-type: none"> • The collection(s) from which an infected recipient received a blood component
Donors At Risk of Transmitting WNV	<ul style="list-style-type: none"> • Measured fever with headache or with other WNV symptoms within 7 days prior to and 14 days after donation • Recent diagnosis of WNV infection AND donated blood within 14 days prior to and 28 days after onset of symptoms • Recent confirmed positive test for WNV NAT • Determined to be potentially associated with a case of transfusion transmitted WNV
Donors Potentially Associated with Transfusion Transmitted WNV	<ul style="list-style-type: none"> • A recipient is later diagnosed with WNV AND • The recipient received blood components from the donor within 28 days before the onset of symptoms in the recipient.
Patients Potentially Associated with Transfusion Transmitted WNV	<ul style="list-style-type: none"> • Diagnosis of WNV infection AND • Received blood transfusions or organs within 28 days preceding onset of symptoms

Donor Screening and Deferral

Perform the following 8 steps to screen the donor for possible WNV infection.

Step	Action
1	Provide each allogeneic and autologous donor with the WNV information contained in Attachment A.

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Donor Screening and Deferral (continued)

Step	Action										
2	Ask the donor if they read and understood the WNV information provided to them.										
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; text-align: center;">If the donor ...</th> <th style="width: 50%; text-align: center;">Then ...</th> </tr> </thead> <tbody> <tr> <td>Understands the WNV information provided</td> <td>Continue</td> </tr> <tr> <td>Does NOT understand the WNV information provided</td> <td>Explain and answer any questions for the donor</td> </tr> </tbody> </table>	If the donor ...	Then ...	Understands the WNV information provided	Continue	Does NOT understand the WNV information provided	Explain and answer any questions for the donor				
If the donor ...	Then ...										
Understands the WNV information provided	Continue										
Does NOT understand the WNV information provided	Explain and answer any questions for the donor										
3	Ask the donor the following WNV screening question: “In the past 7 days, have you had an unexplained, measured fever of greater than 100.4 °F (38°C) associated with a headache”?										
4	Determine whether or not the donor is deferred for possible WNV:										
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; text-align: center;">If the donor ...</th> <th style="width: 50%; text-align: center;">Then the donor is ...</th> </tr> </thead> <tbody> <tr> <td>Answers NO to the WNV screening question</td> <td>NOT deferred for WNV infection</td> </tr> <tr> <td>Answers YES to the WNV screening question</td> <td>Deferred for 28 days from the date of interview</td> </tr> <tr> <td>Has a history of or reports a confirmed positive test for WNV NAT on any previous donation</td> <td>Deferred temporarily until re-instated in accordance with the WNV NAT testing protocol and Service-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation.</td> </tr> <tr> <td>Had a recent diagnosis of WNV infection</td> <td>Deferred for 28 days from the onset of illness or 14 days after the condition is considered to be resolved, whichever date is later.</td> </tr> </tbody> </table>	If the donor ...	Then the donor is ...	Answers NO to the WNV screening question	NOT deferred for WNV infection	Answers YES to the WNV screening question	Deferred for 28 days from the date of interview	Has a history of or reports a confirmed positive test for WNV NAT on any previous donation	Deferred temporarily until re-instated in accordance with the WNV NAT testing protocol and Service-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation.	Had a recent diagnosis of WNV infection	Deferred for 28 days from the onset of illness or 14 days after the condition is considered to be resolved, whichever date is later.
If the donor ...	Then the donor is ...										
Answers NO to the WNV screening question	NOT deferred for WNV infection										
Answers YES to the WNV screening question	Deferred for 28 days from the date of interview										
Has a history of or reports a confirmed positive test for WNV NAT on any previous donation	Deferred temporarily until re-instated in accordance with the WNV NAT testing protocol and Service-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation.										
Had a recent diagnosis of WNV infection	Deferred for 28 days from the onset of illness or 14 days after the condition is considered to be resolved, whichever date is later.										

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Donor Screening and Deferral (continued)

Step	Action				
	<table border="1"> <thead> <tr> <th data-bbox="542 541 1019 577">If the donor ...</th> <th data-bbox="1019 541 1382 577">Then the donor is ...</th> </tr> </thead> <tbody> <tr> <td data-bbox="542 577 1019 730">Has been notified that a previous donation is potentially associated with transfusion transmitted WNV infection</td> <td data-bbox="1019 577 1382 730">Deferred for 28 days from the date of the implicated donation</td> </tr> </tbody> </table>	If the donor ...	Then the donor is ...	Has been notified that a previous donation is potentially associated with transfusion transmitted WNV infection	Deferred for 28 days from the date of the implicated donation
If the donor ...	Then the donor is ...				
Has been notified that a previous donation is potentially associated with transfusion transmitted WNV infection	Deferred for 28 days from the date of the implicated donation				
5	Document whether or not the donor is deferred for possible WNV infection IAW facility-specific SOPs.				
6	If donor is deferred, enter deferral in DBSS using DBSS Temporary Deferral Code 906.				
7	<p>Encourage donors to report any information listed below that later becomes known to them after their donation:</p> <ul style="list-style-type: none"> • Unreported measured fever of greater than 100.4 °F (38°C) associated with headache, occurring within 7 days prior to donation. • Unexplained measured fever of greater than 100.4 °F (38°C) associated with headache or associated with other symptoms suggestive of WNV infection, occurring within 14 days after donation. • Notification that one of their blood donations tested confirmed positive for WNV NAT. • Recent diagnosis of WNV infection. • Notification that one of their donations is suspected of being potentially associated with transfusion transmitted WNV infection in a transfusion recipient. 				

WNV Testing

When WNV test kits are available for use, perform the following 5 steps to test all homologous and autologous donors for possible WNV infection.

NOTE: Tests will be performed using the nucleic acid testing (NAT) methodology, will initially be performed under investigational procedures, and will subsequently be performed using a licensed test when available.

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

WNV Testing (continued)

Step	Action						
1	Test the donation for WNV in accordance with NAT testing protocols and facility-specific SOPs.						
2	Determine if the donor is confirmed positive for WNV in accordance with NAT testing protocols.						
3	Use the following criteria for product management and donor deferral based on the results of WNV NAT.						
	<table border="1"> <thead> <tr> <th data-bbox="553 772 943 804">If the donor....</th> <th data-bbox="943 772 1373 804">Then...</th> </tr> </thead> <tbody> <tr> <td data-bbox="553 804 943 919">Tests negative for WNV NAT</td> <td data-bbox="943 804 1373 919"> <ul style="list-style-type: none"> • Make blood components available and do not defer donor </td> </tr> <tr> <td data-bbox="553 919 943 1329">Tests confirmed positive for WNV NAT</td> <td data-bbox="943 919 1373 1329"> <ul style="list-style-type: none"> • Quarantine and destroy all components • Temporarily defer donor until re-instated in accordance with WNV NAT testing protocols and facility-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation. </td> </tr> </tbody> </table>	If the donor....	Then...	Tests negative for WNV NAT	<ul style="list-style-type: none"> • Make blood components available and do not defer donor 	Tests confirmed positive for WNV NAT	<ul style="list-style-type: none"> • Quarantine and destroy all components • Temporarily defer donor until re-instated in accordance with WNV NAT testing protocols and facility-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation.
If the donor....	Then...						
Tests negative for WNV NAT	<ul style="list-style-type: none"> • Make blood components available and do not defer donor 						
Tests confirmed positive for WNV NAT	<ul style="list-style-type: none"> • Quarantine and destroy all components • Temporarily defer donor until re-instated in accordance with WNV NAT testing protocols and facility-specific SOPs. The donor may NOT be re-instated any sooner than 28 days after the date of the confirmed positive donation. 						
4	If donor is deferred, document donor deferral for WNV NAT in accordance with facility-specific SOPs.						
5	If donor is deferred, enter deferral in DBSS using DBSS Temporary Deferral Code 906.						

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Lookback and Post Donation Information

Perform the following 7 steps for donor and patient lookback when a donor tests confirmed positive for WNV NAT or WNV related post donation information (PDI) is received.

NOTE: Quarantine and retrieval of previously collected components applies to collections of Whole Blood and blood components intended for transfusion, as well as unpooled Source plasma, recovered plasma, and Source Leukocytes intended for further manufacturing into injectable and non-injectable products. Quarantine and retrieval is not recommended for those products that have been pooled for fractionation.

Step	Action	
1	Perform the following steps for product identification/retrieval:	
	<p>If PDI is received about ...</p>	<p>Then promptly identify and locate all in-date products...</p>
	<ul style="list-style-type: none"> • Donors with mild symptoms of upper respiratory infection unassociated with fever OR • Donors with only mosquito bites 	<p>NOT required or recommended.</p>
	<p>Donors with an unexplained measured fever of >100.4 °F (>38°C) associated with headache or associated with other symptoms suggestive of WNV infection, occurring within 7 days prior to or 14 days after donation.</p>	<p>Collected within 14 days prior to and 28 days after the onset of symptoms in donor.</p>
	<p>Donors testing confirmed positive for WNV NAT on a blood donation.</p>	<p>Collected within 14 days prior to and 28 days after the date of the initial positive blood donation.</p>

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV),

Lookback and Post Donation Information (continued)

Step	Action									
	Donors with a recent diagnosis of WNV infection.	Collected within 14 days prior to and 28 days after the onset of illness in the donor.								
	If PDI is received about ...	Then promptly identify and locate all in-date products...								
	Patients with recent diagnosis of WNV infection who received blood transfusions or organ donations within the 28 days preceding the onset of WNV symptoms.	Of all "suspect" donations that were transfused to the WNV patient AND all previous donations from the potentially associated donors that were collected within 28 days prior to and 28 days after the "suspect" donation(s).								
	Donors suspected of being potentially associated with transfusion transmitted WNV infection in a recipient	Associated with "suspect" donation and all previous donations collected within 28 days prior to and 28 days after the "suspect" donation								
2	Perform the following steps for product management, consignee notification, and recipient notification:									
	<table border="1"> <thead> <tr> <th data-bbox="558 1388 899 1423">If products are/were...</th> <th data-bbox="899 1388 1401 1423">Then....</th> </tr> </thead> <tbody> <tr> <td data-bbox="558 1423 899 1499">Available</td> <td data-bbox="899 1423 1401 1499">Quarantine and destroy all blood products. Document disposition.</td> </tr> <tr> <td data-bbox="558 1499 899 1614">Shipped</td> <td data-bbox="899 1499 1401 1614">Notify consignee(s) to quarantine and destroy all products. Document notification.</td> </tr> <tr> <td data-bbox="558 1614 899 1648">Destroyed</td> <td data-bbox="899 1614 1401 1648">Document disposition.</td> </tr> </tbody> </table>		If products are/were...	Then....	Available	Quarantine and destroy all blood products. Document disposition.	Shipped	Notify consignee(s) to quarantine and destroy all products. Document notification.	Destroyed	Document disposition.
	If products are/were...	Then....								
	Available	Quarantine and destroy all blood products. Document disposition.								
	Shipped	Notify consignee(s) to quarantine and destroy all products. Document notification.								
Destroyed	Document disposition.									
Available	Quarantine and destroy all blood products. Document disposition.									
Shipped	Notify consignee(s) to quarantine and destroy all products. Document notification.									
Destroyed	Document disposition.									

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Lookback and Post Donation Information (continued)

Step	Action	
	Transfused AND donor illness is a medical diagnosis of WNV	<u>Identify and Notify prior recipients</u> of the potential WNV transfusion risk. (Relevant units are those dating from 14 days prior through 28 days after the onset of illness of the donor).
	If products are/were...	Then....
	Transfused but donor illness is NOT medical diagnosis of WNV	<u>Do NOT notify prior recipients</u> of blood components collected from that donor.
	Transfused and potentially associated with transmission of WNV to a transfusion recipient, but NOT confirmed through epidemiological investigation	<u>Do NOT notify prior recipients</u> of blood components collected from that donor
	Transfused and the likely source of transmission of WNV to a transfusion recipient, AND confirmed through epidemiological investigation	<u>Identify and notify prior recipients</u> of blood components collected from that donor of the potential WNV transfusion risk. (Relevant units are those dating from 28 days prior to 28 days after the date of the donation that is implicated in transmission of WNV).

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Lookback and Post Donation Information (continued)

3	IAW Command and Navy Environmental Health Center (NEHC) procedures, notify local public health personnel and Navy Blood Program Offices of donors diagnosed with or potentially infectious for WNV and of any transfusion recipients potentially at risk for WNV transfusion transmitted infection.						
4	Follow NEHC directed protocols for shipment of patient samples for further study (757) 953-0700. <ul style="list-style-type: none"> Additional information on laboratory samples for CDC can be found at http://www.cdc.gov/ncidod/dybid/westnile/clinical_guidance.htm 						
	<table border="1"> <thead> <tr> <th>If samples are ...</th> <th>Then ...</th> </tr> </thead> <tbody> <tr> <td>Needed for further testing</td> <td>Ship IAW NEHC or NBPO directions</td> </tr> <tr> <td>NOT needed</td> <td>Discard IAW local policy</td> </tr> </tbody> </table>	If samples are ...	Then ...	Needed for further testing	Ship IAW NEHC or NBPO directions	NOT needed	Discard IAW local policy
If samples are ...	Then ...						
Needed for further testing	Ship IAW NEHC or NBPO directions						
NOT needed	Discard IAW local policy						
Step	Action						
5	Document PDI and lookback IAW facility -specific SOPs.						
6	If donor is deferred, enter donor deferral in DBSS using temporary deferral code 906. (See Donor Screening and Deferral section of the document, for appropriate donor deferral criteria)						
7	Submit Biologic Product Deviation (BPD) reports, IAW Navy Blood Program QA SOPs, in instances of post-donation information related to WNV in cases where:						
	<table border="1"> <thead> <tr> <th>A suspect blood product ...</th> <th>Then a BPD is ...</th> </tr> </thead> <tbody> <tr> <td>Was retrieved and quarantined as a result of a WNV PDI report</td> <td>Required, contact Navy Blood Program Office</td> </tr> <tr> <td>Was transfused and resulted in notification of a transfusion recipient</td> <td>Required, contact Navy Blood Program Office</td> </tr> </tbody> </table>	A suspect blood product ...	Then a BPD is ...	Was retrieved and quarantined as a result of a WNV PDI report	Required, contact Navy Blood Program Office	Was transfused and resulted in notification of a transfusion recipient	Required, contact Navy Blood Program Office
A suspect blood product ...	Then a BPD is ...						
Was retrieved and quarantined as a result of a WNV PDI report	Required, contact Navy Blood Program Office						
Was transfused and resulted in notification of a transfusion recipient	Required, contact Navy Blood Program Office						

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Lookback and Post Donation Information (continued)

Step	Action	
	Was transfused and resulted in the fatality of a transfusion recipient	Required, contact Navy Blood Program Office
NOT distributed	NOT required	

CDC Reporting Requirements

To assist in identification of other possible cases of WNV infection potentially associated with transfusion, the FDA also requires that:

If...	And...	Then...
Patient is diagnosed with WNV infection	Patient has received blood transfusion or organs within 28 days preceding onset of WNV symptoms	<ul style="list-style-type: none"> • Possible transfusion transmission of WNV should be reported to the CDC through local public health authorities. AND • Serum or tissue samples should be retained for later studies
Donor is diagnosed with WNV infection	Donor had onset of WNV symptoms within 14 days of blood or organ donation	<ul style="list-style-type: none"> • Possible transfusion transmission of WNV should be reported to the CDC through local public health authorities via NEHC

Continued on next page

Navy Blood Program Policy on Blood Donor Screening, Deferral, and Lookback for West Nile Virus (WNV), Continued

Labeling of Products

Quarantined products that were distributed for research or intended for further manufacturing into Non-Injectable products, must be labeled consistent with recommended labeling described below as applicable:

- “Biohazard” **OR**
 - “Collected from a donor determined to be at risk for West Nile Virus” **OR**
 - “Collected from a donor positive for evidence of infection with West Nile Virus” **OR**
 - “For laboratory research use only” **OR**
 - “Intended only for further manufacturing into non-injectable products”
-

Donor Information About West Nile Virus (WNV)

What is WNV? West Nile Virus infection has been associated with human encephalitis and meningitis. Throughout 2001 and 2002, WNV spread to about half of the US. In 2002, over 4000 cases of WNV illness and 277 deaths were reported. 99% of human cases in 2002 occurred between 2 July and 30 October.

How can I get WNV? WNV is a mosquito borne virus that is primarily transmitted in birds through mosquito bites. WNV can also be transmitted from birds to humans through mosquito bites.

Can WNV be passed by blood transfusion? Yes. The 2002 WNV epidemic involved the first documented cases of WNV transmission through blood transfusion, organ transplantation, from mothers to infants during pregnancy, and possibly during breastfeeding.

Can I donate blood today? The Food and Drug Administration has recommended that donors who have a risk of being infected with WNV do not donate blood for a short interval.

You may NOT donate blood if you...	You must wait....
Had an unexplained measured fever of greater than 100.4 °F (38°C) associated with a headache within the last 7 days OR	At least 28 days from today's attempted donation date
Have been recently diagnosed with WNV infection OR	At least 28 days from the first day of WNV symptoms or until 14 days after the WNV illness is resolved
Have been notified that one of your blood donations tested positive for WNV	Until you are notified that you are eligible to donate again, but at least 28 days after the date of the confirmed positive donation.
Have been notified that one of your previous blood donations is the potential cause of WNV infection in a patient that has been transfused with your blood	At least 28 days after the date of that previous donation.

After you donate blood! Thank for ensuring the safety of the blood supply! As long as you are well and remain well, you need not take any other measures. **However you should notify the blood donor center and see your doctor if:**

- In the 14 days after your donation, you become ill with a fever of 100.4 °F or higher **AND** have cold-flu symptoms **OR**
- You later find out that you meet any of the other restrictions above.

**DONOR CENTER PERSONNEL INSTRUCTIONS FOR
DIRECT ORAL QUESTION (DOQ) FOR WEST NILE VIRUS (WNV)**

This WNV-DOQ must be asked out loud to **EACH** donor at **EACH** donation.
Documentation of the screener's initials in Section V of the DD 572, *Test, AUG 1998*
Beside a printed statement, stamp, or overlay: "WNV-DOQ" confirms the WNV- DOQ was asked.

"IN THE PAST WEEK, HAVE YOU HAD A FEVER WITH HEADACHE?"

- *Donors who answer "Yes" to the question are deferred for 28 days (4 weeks) from the date of the interview.*
 - *Donors who answer "No" to the question are not deferred.*
-

**ACKNOWLEDGMENT OF RECEIPT
AND
IMPLEMENTATION**

Subj: REVISED GUIDELINES FOR WEST NILE VIRUS (WNV) SCREENING, DEFERRAL, TESTING, AND LOOKBACK		
Identifier: BUMED ltr 6539/2.4 Ser M3F2/ 0060	Date: 04 Jun 03	
<p>The Navy Blood Program must monitor receipt and change control at each of the Surgeon General's facility identified under the Food and Drug Administration's License 635. The Navy Blood Program's policy for above subject matter was received and implemented as indicated below.</p> <p>Note: SIGN AND RETAIN ORIGINAL FOR YOUR FILES. COPY AND FAX THIS FORM AS SOON AS POSSIBLE, BUT <u>NO LATER THAN 13 Jun 03</u> TO:</p> <p style="text-align: center;">CHIEF, BUREAU OF MEDICINE AND SURGERY NAVY BLOOD PROGRAM (M2F3) 2300 E STREET, NW WASHINGTON, DC 20372-5300 FAX (202) 762-0930</p>		
Facility:		
Address:		
Base/City:		
State:		Zip Code:
Date Received:	Date Changed:	Date of Complete Implemented:
Implemented (print):	Signature:	Title:
Comments:		
BELOW FOR NAVY BLOOD TRACKING ONLY		
Date Received at M2F3:		Date entered:
Database enter by:		
Comments:		